Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Andersen

Showing results (461-470 of 530) with videos related to

Pageof 53
Sort By:
Biochimica Et Biophysica Acta|April 24, 2009
P-type ATPases as drug targets: tools for medicine and scienceLaure Yatime, Morten J Buch-Pedersen, Maria Musgaard, et al.
The Journal of Experimental Medicine|January 14, 2009
Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activationKerstin Werninghaus, Anna Babiak, Olaf Gross, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 28, 2023
Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 IndividualsMaria Kjaergaard, Katrine Prier Lindvig, Katrine Holtz Thorhauge, et al.
Nature Communications|March 13, 2021
PGC1/PPAR drive cardiomyocyte maturation at single cell level via YAP1 and SF3B2Sean A Murphy, Matthew Miyamoto, Anaïs Kervadec, et al.
The Lancet. Gastroenterology & Hepatology|January 13, 2024
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort studyMads Israelsen, Nikolaj Torp, Stine Johansen, et al.
Journal of Hepatology|March 1, 2024
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver diseaseKatrine Holtz Thorhauge, Georg Semmler, Stine Johansen, et al.
JHEP Reports : Innovation in Hepatology|March 15, 2024
Infections increase the risk of decompensation and death in patients with early alcohol-related liver diseaseStine Johansen, Simon Langkjær, Ditlev Nytoft Rasmussen, et al.
Vaccine|January 25, 2011
Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infectionJaap T van Dissel, Darius Soonawala, Simone A Joosten, et al.
Clinical and Vaccine Immunology : CVI|July 11, 2006
Tuberculosis in elephants: antibody responses to defined antigens of Mycobacterium tuberculosis, potential for early diagnosis, and monitoring of treatmentKonstantin P Lyashchenko, Rena Greenwald, Javan Esfandiari, et al.
American Journal of Respiratory and Critical Care Medicine|August 10, 2018
Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection TrialSara Suliman, Angelique Kany Kany Luabeya, Hennie Geldenhuys, et al.
Pageof 53

Showing results (461-470 of 530) with videos related to

Sort By:
Pageof 53
Biochimica Et Biophysica Acta|April 24, 2009
P-type ATPases as drug targets: tools for medicine and scienceLaure Yatime, Morten J Buch-Pedersen, Maria Musgaard, et al.
The Journal of Experimental Medicine|January 14, 2009
Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activationKerstin Werninghaus, Anna Babiak, Olaf Gross, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 28, 2023
Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 IndividualsMaria Kjaergaard, Katrine Prier Lindvig, Katrine Holtz Thorhauge, et al.
Nature Communications|March 13, 2021
PGC1/PPAR drive cardiomyocyte maturation at single cell level via YAP1 and SF3B2Sean A Murphy, Matthew Miyamoto, Anaïs Kervadec, et al.
The Lancet. Gastroenterology & Hepatology|January 13, 2024
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort studyMads Israelsen, Nikolaj Torp, Stine Johansen, et al.
Journal of Hepatology|March 1, 2024
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver diseaseKatrine Holtz Thorhauge, Georg Semmler, Stine Johansen, et al.
JHEP Reports : Innovation in Hepatology|March 15, 2024
Infections increase the risk of decompensation and death in patients with early alcohol-related liver diseaseStine Johansen, Simon Langkjær, Ditlev Nytoft Rasmussen, et al.
Vaccine|January 25, 2011
Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infectionJaap T van Dissel, Darius Soonawala, Simone A Joosten, et al.
Clinical and Vaccine Immunology : CVI|July 11, 2006
Tuberculosis in elephants: antibody responses to defined antigens of Mycobacterium tuberculosis, potential for early diagnosis, and monitoring of treatmentKonstantin P Lyashchenko, Rena Greenwald, Javan Esfandiari, et al.
American Journal of Respiratory and Critical Care Medicine|August 10, 2018
Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection TrialSara Suliman, Angelique Kany Kany Luabeya, Hennie Geldenhuys, et al.
Pageof 53